PUBLISHER: DelveInsight | PRODUCT CODE: 1378002
PUBLISHER: DelveInsight | PRODUCT CODE: 1378002
“"PK101 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about PK101 for osteoarthritis in the six major markets. A detailed picture of the PK101 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the PK101 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PK101 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.
PK101 is a nonsteroidal anti-inflammatory analgesic (NSAID) product with increased effectiveness and reduced cardiovascular and gastrointestinal side effects. It is a combination of natural and synthetic drugs. Arthritis is a disease that requires long-term administration to elderly patients, and the market size of natural medicines is increasing in response to the demand for safe drugs. A Phase III clinical trial to verify the efficacy and safety of PK101 in patients with knee OA is underway at 10 institutions, and the total number of subjects is 354. Participating institutions are 10 centers, including Chonbuk National University Hospital, Ajou University Hospital, Busan Paik Hospital, and rheumatology departments nationwide.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PK101 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of PK101 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of PK101 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions